Lynk Pharmaceuticals announced administration of the first patient in the Phase II clinical study of LNK01001

HANGZHOU, China, December 1, 2021 / PRNewswire / – Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as “Lynk Pharmaceuticals”), an innovative clinical phase company, announced that the company has administered LNK01001 to the first patient as part of its phase II clinical trial in subjects with rheumatoid arthritis (RA) . LNK01001 is a targeted inhibitor for the treatment of autoimmune diseases.

The clinical study is designed to assess the safety and efficacy of LNK01001 in subjects with moderate to severe active rheumatoid arthritis who have a poor response or intolerance to conventional synthetic anti-rheumatic drugs (csDMARD).

LNK01001 is the first innovative drug developed by Lynk Pharmaceuticals, and is a selective kinase inhibitor for the treatment of autoimmune diseases. Previously, LNK01001 completed phase I clinical studies in healthy subjects during the summer of this year in China and in Australia and Japan, sponsored respectively by Lynk Pharmaceuticals and its American partner. The results showed that the drug is safe and well tolerated. Additionally, LNK01001 has been approved by the National Medical Products Administration of China (NMPA) for the clinical evaluation of new indications – ankylosing spondylitis (AS) and atopic dermatitis (AD).

Professor Xiaofeng zeng, the principal investigator of this study and the director of the Department of Rheumatology and Immunology at Peking Union Medical College Hospital and the Chinese Academy of Medical Sciences, said, “Rheumatoid arthritis is a chronic and progressive autoimmune disease. , if not treated in time, it will lead to systemic disability and complications, severely affecting the quality of life and physical health of patients.LNK01001 has demonstrated a good safety profile and a positive PD marker response in patients. Phase I studies, I am pleased to be leading the Phase II clinical trial with many excellent clinicians, and we will do our best to bring new therapy to patients as soon as possible. ”

“Rheumatoid arthritis is a chronic and usually progressive autoimmune disease that causes functional disability, severe pain and joint destruction, and leads to premature death. Globally, this disease has a heavy disease burden and its clinical requirements for optimal therapy for disease management are far from being met. The results of our Phase I clinical research on LNK01001 showed a favorable safety profile and tolerability. “Dr. Sherry Weigand, Lynk Pharmaceuticals Medical Director, said: “Reaching the first patient for the Phase II clinical trial of LNK01001 is an important milestone for the development of LNK01001, and we expect this innovative drug to bring new treatment options for RA. disease management. ”

About Lynk Pharmaceuticals:

Lynk Pharmaceuticals, a clinical stage company, was founded in 2018 by senior drug R&D experts and executives from Pfizer, Merck and Johnson & Johnson. Lynk Pharmaceuticals is dedicated to the discovery and development of innovative drugs for the treatment of cancer, as well as immune and inflammatory diseases. Driven by a higher goal, Lynk Pharmaceuticals aims to be a market leader in meeting unmet medical demands through the development of innovative therapies. To date, Lynk Pharmaceuticals has independently developed a number of new innovative Class I clinical drugs and, independently and jointly with its US partner, has initiated a number of clinical studies globally. For more information about Lynk Pharmaceuticals, please visit: https://www.lynkpharma.com.

SOURCE Lynk Pharmaceuticals Co., Ltd.


Source link

Comments are closed.